As Klf15 is part of the GC-GR-KLF15-BCAA pathway, previously shown to be dysregulated in SMA muscle, it is possible that mifepristone treatment in animal models or SMA patients may modulate BCAA levels. The gene discussed is GC; the disease is proximal spinal muscular atrophy.